CRISPR Therapeutics AG (CRSP) has a consensus analyst rating of Buy, based on 38 analysts covering the stock. Of those, 22 recommend buying, 14 recommend holding, and 2 recommend selling.
The analyst consensus price target for CRSP is $65.00, representing a +14.3% upside from the current price of $56.86. Price targets range from a low of $33.00 to a high of $82.00.
